

1 **WO**

2  
3  
4  
5  
6 **IN THE UNITED STATES DISTRICT COURT**  
7 **FOR THE DISTRICT OF ARIZONA**  
8

9 Jacque Duhame,

10 Plaintiff,

11 v.

12 Sanofi SA, et al.,

13 Defendants.  
14

No. CV-23-02415-PHX-MTL

**ORDER**

15 Before the Court is Plaintiff Jacque Duhame’s Motion for Leave to File an Amended  
16 Complaint (Doc. 20). The motion is fully briefed.<sup>1</sup> (Docs. 20, 21.) For the forthcoming  
17 reasons, the Court denies Plaintiff’s motion (Doc. 20).

18 **I. BACKGROUND**

19 This case comes before the Court after being transferred from a multidistrict  
20 litigation consolidation (“MDL”) in the Eastern District of Louisiana. (Doc. 7.) More than  
21 15,000 plaintiffs claim that Taxotere, a chemotherapy drug, causes permanent  
22 chemotherapy induced alopecia (“PCIA”) and that Defendants were aware of this side  
23 effect but failed to warn patients. (Doc. 6-1 at 71-72.)

24 Plaintiff’s operative pleadings include the second amended master complaint, (Doc.  
25 6-4 at 342-411), and her short form complaint (“SFC”), (Doc. 1). The second amended  
26 master complaint defined Plaintiff’s injury as hair loss persisting six months after  
27 completion of chemotherapy. (*Id.* at 377-78.) The SFC follows a standardized template,

28  

---

<sup>1</sup> Plaintiff did not file a reply brief, and the deadline to do so has passed. *See* LRCiv 7.2(d).

1 including fill-in-the-blank spaces and check-boxes to identify the parties, jurisdiction,  
2 venue, injuries, and claims incorporated from the master complaint. (Doc. 1.) Defendants’  
3 operative pleading is its master answer. (Doc. 6-4 at 246-341.)

4 During the MDL proceedings in 2019, the MDL plaintiffs requested leave to file a  
5 third amended complaint to redefine their alleged injury as “[t]here is no single definition  
6 for [PCIA] and the amount of time to establish permanent hair loss varies from patient to  
7 patient, including among [p]laintiffs.” (Doc. 6-4 at 412, 458, 1425-26.) The MDL court  
8 denied the motion reasoning that the parties and the MDL court had “been operating under  
9 [p]laintiffs’ original definition of their alleged injury” since 2017. (*Id.* at 1427-29.)

10 In May 2020, the MDL court issued Pretrial Order No. 105 (“PTO 105”), “Short  
11 Form Complaint Allegations and Amendments – Statute of Limitations Order,” in light of  
12 the MDL court’s rulings related to statute of limitations, *In re Taxotere (Docetaxel) Prods.*  
13 *Liab. Litig.*, MDL No. 16-2740, 2019 WL 2995897 (E.D. La. July 9, 2019). (Doc. 6-2 at  
14 167-171.) PTO 105 gave MDL plaintiffs the opportunity “to add factual allegations  
15 regarding particularized facts individual and specific to each [p]laintiff’s medical care and  
16 treatment and/or that [p]laintiff’s communications with medical professionals” within 180  
17 days if the Order. (*Id.* at 167.) The parties later stipulated to extend the deadline to January  
18 15, 2021. (*Id.* at 169-170.) Plaintiff did not amend her SFC before this deadline. (*See* Doc.  
19 1; Doc. 20.)

20 After the completion of general discovery and bellwether trials, Plaintiff’s case was  
21 transferred out of the MDL court to this Court in October 2023. (Doc. 7.) The Transfer  
22 Order provided that “[a]ll deadlines for [p]laintiffs to amend their individual complaints  
23 without leave of court have passed.” (Doc. 7 at 76.)

24 In January 2024, this Court held a scheduling conference and issued a scheduling  
25 order setting deadlines for this specific case. (Docs. 15, 16.) The parties agreed to set the  
26 deadline to file a motion to amend the pleadings to February 2, 2024, which the Court  
27 entered in the case-specific Scheduling Order. (Doc. 14 at 10; Doc. 16 at 1.)

28 Plaintiff filed a timely motion to amend her complaint. (Doc. 20.) Defendants

1 oppose the motion. (Doc. 21.)

## 2 **II. LEGAL STANDARD**

3 Under Rule 15, “[t]he court should freely grant leave [to amend] when justice so  
4 requires.” Fed. R. Civ. P. 15(a)(2). Leave may be denied, however, for reasons such as  
5 “undue delay, bad faith or dilatory motive on the part of the movant, repeated failure to  
6 cure deficiencies by amendments previously allowed, undue prejudice to the opposing  
7 party by virtue of allowance of the amendment, [or] futility of amendment.” *Foman v.*  
8 *Davis*, 371 U.S. 178, 182 (1962). The Ninth Circuit has held that prejudice to the opposing  
9 party is the strongest factor and that absent prejudice, or “a strong showing” of the other  
10 factors, a “presumption” exists in favor of granting the leave to amend. *Eminence Cap.,*  
11 *LLC v. Aspeon, Inc.*, 316 F.3d 1048, 1052 (9th Cir. 2003).

## 12 **III. ANALYSIS**

13 Plaintiff requests leave to file an amended complaint under Rule 15, Fed. R. Civ. P,  
14 so she can allege facts specific to her. (Doc. 20 at 5.) Plaintiff argues she was unable to  
15 allege case-specific facts because she was “beholden to the master complaint, incorporated  
16 by reference into the MDL’s standardized SFC.” (*Id.* at 3.) Plaintiff’s amendments fall into  
17 the following categories: “(1) to provide case-specific facts supportive of Plaintiff’s claims  
18 in compliance with Fed. R. Civ. P. 8; (2) to clarify an important issue in this case  
19 concerning when Plaintiff knew of the link between her permanent hair loss and  
20 Defendants’ actionable conduct; (3) to plead claims and allegations specific to the  
21 underlying substantive law; and (4) to narrow the issues and omit allegations related to  
22 other MDL defendants and plaintiffs that are not parties in this matter.” (*Id.* at 7.)

23 Defendants argue that under the law of the case doctrine, this Court should leave the  
24 MDL court’s rulings intact as other transferor courts have done. (Doc. 21 at 2.) Defendants  
25 maintain that the MDL scheduling order provided an opportunity for Plaintiff to amend her  
26 SFC to include her case-specific facts and that deadline has passed. (*Id.* at 2-5.) Defendants  
27 also argue that allowing Plaintiff to amend her pleading now “would fundamentally alter  
28 this litigation and severely prejudice” Defendants. (*Id.* at 5-10.)

1 Under the law of the case doctrine, “when a court decides upon a rule of law, that  
2 decision should continue to govern the same issues in subsequent stages in the same case.”  
3 *Arizona v. California*, 460 U.S. 605, 618 (1983). Although this Court has discretion to  
4 reconsider previous rulings, it “should be loath to do so in the absence of extraordinary  
5 circumstances such as where the initial decision was clearly erroneous and would work a  
6 manifest injustice.” *Christianson v. Colt Indus. Operating Corp.*, 486 U.S. 800, 817 (1988)  
7 (cleaned up). In the context of transfer from an MDL court, “exceptions to the law of the  
8 case principle should be especially rare . . . because refusal to follow the previous ruling  
9 would result in the sort of piecemeal decision making that MDL centralization is intended  
10 to avoid.” Wright & Miller, 15 Fed. Prac. & Proc. Juris. § 3867 (4th ed., Apr. 2023 Update).  
11 “If transferor judges were permitted to upset the rulings of transferee judges, the result  
12 would be an undermining of . . . Section 1407 [of Title 28 U.S.C.] for coordinated or  
13 consolidated pretrial proceedings because those proceedings would then lack the  
14 finality . . . requisite to the convenience of . . . parties and to efficient conduct of actions.”  
15 Stanley A. Weigel, *The Judicial Panel on Multidistrict Litigation, Transferor Courts and*  
16 *Transferee Courts*, 78 F.R.D. 575, 577 (1978).

17 Here, Plaintiff’s proposed amended complaint violates the MDL court’s prior  
18 Orders. Plaintiff’s proposed amended complaint changes the claims originally alleged and  
19 includes (1) factual allegations specific to her medical care, treatment, and communications  
20 with medical professionals, (2) factual allegations to establish equitable tolling, and  
21 (3) excludes the six-month injury definition. (*See* Doc. 21-1.)

22 The MDL court’s December 12, 2019 Order rejected the request to change the injury  
23 definition when it denied the MDL plaintiffs’ motion to file a third amended master  
24 complaint. (Doc. 6-4 at 1425-29.) Plaintiff does not argue that the MDL court erred in  
25 denying the amendment. (*See* Doc. 20.) Allowing Plaintiff to amend her complaint now so  
26 that it no longer includes an injury definition would violate the MDL court’s prior order,  
27 disrupting the law of the case, and be unduly prejudicial to Defendants. *See Jean Anderson*  
28 *v. Sanofi-Aventis U.S. LLC et al.*, 2024 WL 1601869, at \*2-3 (C.D. Cal. Jan. 19, 2024)

1 (denying a different MDL plaintiff’s motion for leave to amend the injury definition finding  
2 allowing the amendment would be “unduly prejudicial” to defendants); *Carol Allain v.*  
3 *Sanofi-Aventis U.S. LLC*, 2024 WL 1641747, at \*1-\*2 (M.D. Fla. Feb. 26, 2024) (same).

4 Plaintiff also argues that this stipulation put a “pin” in the issue of amendment,  
5 meaning that PTO 105 does not preclude her from seeking to amend her SFC now. (Doc.  
6 20 at 4.) When extending the deadline for PTO 105, the parties stipulated that:

7  
8 2. Plaintiffs agree not to seek leave to amend SFCs to add or  
9 include any allegations that are inconsistent with PTO 105 or  
10 this Court’s Orders addressing motions to amend SFCs,  
11 including any allegations that have been previously disallowed  
12 by the Court;

13 3. If a Defendant seeks dismissal of any case based on a statute  
14 of limitations, it agrees that it will not argue waiver based on  
15 any Plaintiff’s refraining from amending her SFC to include  
16 allegations inconsistent with PTO 105, as described in  
17 paragraph 2 hereinabove;

18 (Doc. 6-2 at 169.)

19 This stipulation may allow amendments inconsistent with PTO 105, because  
20 Defendants agreed to “not argue waiver based on any Plaintiff’s refraining from amending  
21 her SFC to include allegations *inconsistent with PTO 105.*” (Doc. 6-2 at 169.) Plaintiff’s  
22 proposed amended complaint, however, includes the types of amendments contemplated  
23 by PTO 105. Pursuant to PTO 105, Plaintiff had the opportunity to add factual allegations  
24 specific to her medical care, treatment, and communications with medical professionals—  
25 including factual allegations of discovery of injury to allege statute of limitations tolling.  
26 (See Doc. 6-2 at 167.) Allowing Plaintiff to make such amendments at this late stage, more  
27 than 3-years after the deadline, would be prejudicial to Defendants. Plaintiff has not  
28 explained why she did not make these amendments when given the opportunity to do so  
before the January 2021 deadline. (See Doc. 20.)

Moreover, as discussed at the January 18, 2024 scheduling conference, Defendants  
do not intend to challenge Plaintiff’s pleadings but instead anticipate seeking summary


1 judgment based on the case-specific discovery to challenge statute of limitations. (Doc. 15  
2 at 15.) Plaintiff also conceded that by virtue of Arizona law that discovery would be  
3 necessary to determine statute of limitations, making it a summary judgment issue. (*Id.* at  
4 3-4.) Without a better explanation of why amendment is necessary and why she did not  
5 comply with PTO 105 by amending her pleading before January 15, 2021, the Court is  
6 unpersuaded that Plaintiff's amendment is appropriate now. *See Jean Anderson*, 2024 WL  
7 1601869, at \*3-\*4.

8 **IV. CONCLUSION**

9 Accordingly,

10 **IT IS ORDERED denying** Plaintiff's Motion for Leave to File an Amended  
11 Complaint (Doc. 20).

12 Dated this 30th day of April, 2024.

13  
14 

15 \_\_\_\_\_  
16 Michael T. Liburdi  
17 United States District Judge  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28